| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Abemaciclib: A Review in Early Breast Cancer with a High Risk of Recurrence
|
Fung, Simon
|
|
|
18 |
2 |
p. 287-294
|
artikel
|
| 2 |
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan
|
Hsu, Ping-Chih
|
|
|
18 |
2 |
p. 195-207
|
artikel
|
| 3 |
Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma
|
Lee, Nuri
|
|
|
18 |
2 |
p. 247-255
|
artikel
|
| 4 |
Comparison of Outcomes Between Therapeutic Combinations Based on Immune Checkpoint Inhibitors or Tyrosine Kinase Inhibitor Monotherapy for First-Line Therapy of Patients with Advanced Renal Cell Carcinoma Outside of Clinical Trials: A Real-World Retrospective Multi-Institutional Study
|
Ishihara, Hiroki
|
|
|
18 |
2 |
p. 209-220
|
artikel
|
| 5 |
Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies
|
Popat, Sanjay
|
|
|
18 |
2 |
p. 311
|
artikel
|
| 6 |
First-in-Human Study of INCB062079, a Fibroblast Growth Factor Receptor 4 Inhibitor, in Patients with Advanced Solid Tumors
|
Harding, James J.
|
|
|
18 |
2 |
p. 181-193
|
artikel
|
| 7 |
FT-6876, a Potent and Selective Inhibitor of CBP/p300, is Active in Preclinical Models of Androgen Receptor-Positive Breast Cancer
|
Caligiuri, Maureen
|
|
|
18 |
2 |
p. 269-285
|
artikel
|
| 8 |
Long-Term Real-World Outcomes and Safety of Vemurafenib and Vemurafenib + Cobimetinib Therapy in Patients with BRAF-Mutated Melanoma
|
Piejko, Karolina
|
|
|
18 |
2 |
p. 235-245
|
artikel
|
| 9 |
Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunichLMU Molecular Tumor Board
|
Dorman, Klara
|
|
|
18 |
2 |
p. 257-267
|
artikel
|
| 10 |
Real-World Data for Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma: How Does Adherence to the IMbrave150 Trial Inclusion Criteria Impact Prognosis?
|
Rimini, Margherita
|
|
|
18 |
2 |
p. 221-233
|
artikel
|
| 11 |
Relugolix: A Review in Advanced Prostate Cancer
|
Shirley, Matt
|
|
|
18 |
2 |
p. 295-302
|
artikel
|
| 12 |
Selinexor–Bortezomib–Dexamethasone: A Review in Previously Treated Multiple Myeloma
|
Syed, Yahiya Y.
|
|
|
18 |
2 |
p. 303-310
|
artikel
|
Tijdschrift beschrijving